

1 **National Advisory Committee (NAC)**
2 **for Acute Exposure Guideline Levels (AEGLs) for Hazardous Substances**

3
4 **December 3-5, 2008**
5

6 **Final Meeting-47 Highlights**

7
8 **Holiday Inn**
9 **1355 North Harbor Drive**
10 **San Diego, CA**
11

12
13
14 **INTRODUCTION**

15
16
17 George Rusch opened the meeting which was followed by introductions of all participants.
18

19 The draft NAC/AEGL-46 meeting highlights were reviewed. A motion to accept the minutes as
20 written was made by Dieter Heinz (second by Henry Anderson) and passed unanimously
21 (Appendix A). The Final NAC/AEGL-46 meeting highlights are included as Appendix B.
22

23 Ernie Falke provided a status update on the National Academy of Science (NAS) publications.
24 Volume 6 is published and additional volumes are under way. The Technical Support Document
25 (TSD) and AEGL values for carbon monoxide can be finalized.
26

27 The highlights of the NAC/AEGL-47 meeting are summarized below along with the Meeting
28 Agenda (Attachment 1) and the Attendee List (Attachment 2). The subject categories of the
29 highlights do not necessarily follow the order listed in the NAC/AEGL-47 Agenda.
30
31
32

33 **STANDING OPERATING PROCEDURES (SOP) REVISIONS**

34
35 Ernie Falke briefly described the status of the SOP addendum. The committee asked for a list of
36 SOP issues at the next AEGL meeting. The Physiologically-Based Pharmacokinetic Modeling
37 (PBPK) white paper will be posted on the AEGL website. In addition, TSD postings are under
38 way. Only clean TSDs (not markup documents) will be posted on the AEGL website. The
39 AEGL website is being revised and a new format will be posted in December. The committee
40 requested to be informed when the new format is available. Therefore, an email will be sent to
41 the committee members when the new website is available.
42
43
44
45
46
47

LOA DISCUSSION

The LOA paper is scheduled to be published as an RIVM publication in December and should be available on the website in 2009. Also, the paper will be sent to Don Gardner for publication in *Inhalation Toxicology*.

CHEMICAL LIST

There was considerable discussion regarding the source and criteria for chemicals to be considered for AEGL development. Possible criteria for adding a chemical to the priority list included sufficient vapor pressure, production and use data, and toxicity sufficient for concern. The NAC felt that it was important to know who was nominating chemicals for AEGL development and for what reasons. The committee also discussed putting together a guidance document listing chemical selection criteria and the possibility of publishing a list of tabled chemicals in an FR notice.

CHLOROSILANES GROUPING

Staff Scientist: Cheryl Bast, ORNL

Chemical Manager: Ernest Falke, U.S. EPA

Background information was provided by Cheryl Bast (Attachment 3). The NAC has developed AEGL values for 24 chlorosilanes. Twenty-one of these were developed at NAC-43 and NAC-44, are based on analogy to hydrogen chloride, and are presented in one TSD. The other three (dimethyldichloro-, trimethylchloro-, and methyltrichloro-silanes) were derived prior to NAC-43, are each presented in separate TSDs and values are based on chemical-specific data where available. The proposal is to incorporate all chlorosilanes into one TSD and use the HCl analogy approach for consistency. George Rusch recommended adding the derivation of the individual TSDs as an appendix in the new TSD. The revised TSD will contain all 24 chlorosilanes and derivation will be based on analogy to hydrogen chloride. The revised document should contain a discussion on the impact of bulky groups in the hydrolysis of the chlorosilane. Also, the revised document will include a table of the hydrolysis rates for the various chlorosilanes and will note those that do not have data. A motion (Marcel Van Raaij /John Hinz) was made to adopt the proposed AEGL values for the 3 chlorosilanes under consideration. The motion was approved unanimously (Appendix C: 22 yes; 0 no; 0 abstain).

Compound	Classification	10-min	30-min	1-h	4-h	8-h	Endpoint (Reference)
<u>Trimethylchlorosilane</u>	AEGL-1	1.8 ppm	Hydrogen chloride (HCl) AEGL-1 values adopted as AEGL-1 values (NRC, 2004)				
	AEGL-2	100 ppm	43 ppm	22 ppm	11 ppm	11 ppm	Hydrogen chloride (HCl) AEGL-2 values adopted as AEGL-2 values (NRC, 2004)
	AEGL-3	620 ppm	210 ppm	100 ppm	26 ppm	26 ppm	Hydrogen chloride (HCl) AEGL-3 values adopted as AEGL-3 values (NRC, 2004)
<u>Dimethyldichlorosilane</u>	AEGL-1	0.90 ppm	HCl AEGL-1 values divided by a molar adjustment factor of 2 adopted as AEGL-1 values (NRC, 2004)				
	AEGL-2	50 ppm	22 ppm	11 ppm	5.5 ppm	5.5 ppm	HCl AEGL-2 values divided by a molar adjustment factor of 2 adopted as AEGL-2 values (NRC, 2004)
	AEGL-3	310 ppm	110 ppm	50 ppm	13 ppm	13 ppm	HCl AEGL-3 values divided by a molar adjustment factor of 2 adopted as AEGL-3 values (NRC, 2004)
<u>Methyltrichlorosilane</u>	AEGL-1	0.60 ppm	HCl AEGL-1 values divided by a molar adjustment factor of 3 adopted as AEGL-1 values (NRC, 2004)				
	AEGL-2	33 ppm	14 ppm	7.3 ppm	3.7 ppm	3.7 ppm	HCl AEGL-2 values divided by a molar adjustment factor of 3 adopted as AEGL-2 values (NRC, 2004)
	AEGL-3	210 ppm	70 ppm	33 ppm	8.7 ppm	8.7 ppm	HCl AEGL-3 values divided by a molar adjustment factor of 3 adopted as AEGL-3 values (NRC, 2004)

2

3

4

FEDERAL REGISTER 11- ACRYLONITRILE

5

6 Acrylonitrile (CAS No. 107-13-1) was the only chemical for which comments were received.
7 Comments received from the AN Group on the FR submission for acrylonitrile were summarized
8 by Robert Young (ORNL) (Attachment 4). The AN Group commended the NAC/AEGL for a
9 thorough and thoughtful TSD. The AN Group suggested minor adjustment to uncertainty factor
10 application resulting from PB-PK model results. Because the numerical adjustments were
11 somewhat unorthodox relative to AEGL SOP guidelines and because the PB-PK model results
12 were already incorporated into the development of the proposed AEGL values, it was decided
13 unanimously to retain the original NAC/AEGL assessment. Additional reports regarding
14 developmental/ reproductive studies on AN will be incorporated into the TSD as suggested by
15 the AN Group. Consistent with AN suggestions, the cancer risk section will reflect current
16 assessments of epidemiology reports and IARC decisions regarding no causal relationship for
17 cancer risk from AN exposure. Bob Benson agreed to submit a write-up to this effect. George
18 Woodall will offer the revision to the IRIS staff for comment.

19

20

ORGANOPHOSPHATE (OP) UNCERTAINTY FACTOR ISSUES

21

22
23 John Hinz and George Woodall led a discussion session on OP uncertainty issues in conjunction
24 with a presentation (via teleconference) with Virginia Moser (U.S. EPA ORD) (Attachment 5).
25 General information on the various targets of OPs and the metabolism of OPs were provided
26 with respect to impact on interspecies and intraspecies uncertainty factors. Additionally,
27 summary information for the specific OPs scheduled for discussion at the meeting were also
28 provided. Although uncertainty factor selection and justification is always a chemical-specific
29 issue, inhalation data on OPs are often very limited. Use of default uncertainty factors
30 (currently 3 for interspecies and 10 for intraspecies) selection/justification will require careful
31 consideration on a chemical-by-chemical basis.

1
2
3 **CHEMICAL REVISITS/STATUS UPDATES**
4
5

6 **No Data Chemicals**
7

8 Cheryl Bast (ORNL) provided a status update for aluminum chloride, antimony pentafluoride,
9 phosphorus pentafluoride, and phosphorus pentasulfide. These chemicals have no data and will
10 be placed in holding status.

11 The committee commented on the 12 chemicals that did not have AEGL values (as described in
12 the NAC-46 highlights). The following recommendations were made:

- 13 a. Identify criteria for chemical selection and publish it in the addendum of the SOP. This
14 suggestion was made by Calvin Willhite.
15 b. Publication of tabled chemicals in a FR notice requesting additional data for AEGL
16 development.
17 c. Refer chemicals to groups that have a structure-activity background.
18
19
20

21 **Methyl Iodide (CAS No. 74-88-4)**
22

23 **Staff Scientist: Sylvia Talmage, ORNL**

24 **Chemical Manager: Alan Becker, Missouri St. Univ.**
25

26 A status update was provided by Sylvia Talmage. Industry is still working on the PBPK
27 modeling results for methyl iodide.
28
29

30 **Allyl Alcohol (CAS No. 107-18-6)**
31

32 **Staff Scientist: Claudia Troxel, ORNL**

33 **Chemical Manager: Bob Benson, U.S. EPA**
34

35 Bob Benson, the chemical manger, made brief introductory remarks on this chemical. The
36 chemical has been considered by the NAC and reviewed by the COT multiple times. At the
37 December, 2006, NAC meeting, Dr. Marcy Banton, a representative of Lyondell, the sole US
38 manufacturer of allyl alcohol, offered to ask her company to sponsor an additional study to help
39 resolve the issues that led to the lack of agreement by the COT of the AEGL values derived by
40 the NAC. Dr. Banton was successful in her effort. The new study was completed earlier this
41 year. Dr. Jeff Fowles, the present representative of Lyondell Basell, presented a brief summary
42 of the results of this new study (Attachment 6). Claudia Troxel then began a discussion of the
43 data available on the chemical and the reasons for the previous lack of agreement between the
44 NAC and COT on the AEGL values (Attachment 7). New AEGL-3 values were derived based
45 on the LC₀₁ from all the rat studies showing lethality using the ten Berge regression program
46 with n = 0.95 and a total uncertainty factor of 10 (3 each for interspecies and intraspecies
47 extrapolation). The values are 260 ppm, 82 ppm, 40 ppm, 9.3 ppm, and 4.5 ppm for 10 minutes
48 to 8 hours, respectively. AEGL-2 values were calculated by deriving the AEGL-3 values by 3
49 because the NOEL for severe, irreversible nasal lesions was virtually identical to the exposure-

1 response relationship for lethality. The AEGL-2 values are 87 ppm, 27 ppm, 13 ppm, 3.1 ppm,
 2 and 1.5 ppm for 10 minutes to 8 hours, respectively. John Hinz moved that the AEGL-3 and
 3 AEGL-2 values be accepted. Mark Baril seconded the motion. The motion passed (Appendix
 4 D: 19 yes; 0 no; 1 abstain). Possibilities for AEGL-1 values included the human data for eye
 5 irritation from a 5 minute exposure with values of 2.1 for 10, 30, and 60 minutes, and Not
 6 Recommend for longer durations; the new laboratory animal study in rats showing nasal
 7 inflammation 14 days after exposure (9.3 ppm, 6.4 ppm, 5.1 ppm, 2.2 ppm, and 1.0 ppm for 10
 8 minutes to 8 hours, respectively); the new laboratory animal study in rats showing nasal
 9 degeneration 14 days after exposure (21 ppm, 21 ppm, 6.8 ppm, 0.68 ppm, and 0.21 ppm for 10
 10 minutes to 8 hours, respectively); and the new laboratory animal study in rats showing a
 11 lessening of the startle response during exposure (14 ppm, 5.3 ppm, 3.2 ppm, 0.9 ppm, and 0.5
 12 ppm for 10 minutes to 8 hours, respectively). Bob Benson made the motion to accept the values
 13 based on nasal inflammation. George Woodall seconded the motion. The motion passed
 14 (Appendix D: 20 yes; 0 no; 0 abstain).

15
 16 These discussions identified an SOP issue regarding analysis of data using the ten Berge program
 17 and whether to report only the 1% response or lower limit of the 5% response.
 18

Summary of AEGL Values for Allyl Alcohol						
Classification	10-min	30-min	1-h	4-h	8-h	Endpoint (Reference)
AEGL-1 (Nondisabling)	9.3 ppm	6.4 ppm	5.1 ppm	2.2 ppm	1.0 ppm	Nasal inflammation in rats (Kirkpatrick, 2008)
AEGL-2 (Disabling)	87 ppm	27 ppm	13 ppm	3.1 ppm	1.5 ppm	Severe, irreversible lesions in rats (Kirkpatrick, 2008)
AEGL-3 (Lethal)	260 ppm	82 ppm	40 ppm	9.3 ppm	4.5 ppm	LC ₀₁ (Combined rat data)

19
 20
 21 **REVIEW of PRIORITY CHEMICALS**
 22
 23

24 **Tear Gas (CAS No. 2698-41-1)**
 25

26 **Staff Scientist: Cheryl Bast, ORNL**

27 **Chemical Manager: Glenn Leach, U.S. Army CHPPM**
 28

29 Cheryl Bast presented a summary of the available data and an overview of the development of
 30 proposed AEGL values for tear gas (Attachment 8). Proposed AEGL-1 values were based on
 31 human exposure to 1.5 mg/m³ for 90 minutes (Punte et al., 1963), an exposure tolerated by all 4
 32 subjects but resulting in ocular and nasal irritation and headache. One subject developed nasal
 33 irritation within 2 minutes, three subjects developed headache (at 45, 50, and 83 minutes), and all
 34 four experienced ocular irritation (at 20, 24, 70, and 75 minutes). The intraspecies uncertainty
 35 factor was limited to 3 because contact irritation is a portal-of-entry effect and is not expected to
 36 vary widely among individuals and was supported by the fact that responses of volunteers with
 37 jaundice, hepatitis, or peptic ulcer or those that were 50-60 years old were similar to those of
 38 “normal” volunteers when exposed to a highly irritating concentration of CS for short durations
 39 (Punte et al., 1963; Gutentag et al., 1960). The interspecies uncertainty factor was 1 was due to
 40 the use human data. A modifying factor of 10 was applied to reduce the point-of-departure from

1 a LOEL to a NOAEL for effects defined by AEGL-1. Time scaling was not applied in the
 2 development of the AEGL-1 values, because the critical effect (irritation) is a function of direct
 3 contact with the tear gas and is not likely to increase with duration of exposure at this level of
 4 severity (NRC, 2001). The AEGL-2 values were based on the same point-of departure as the
 5 AEGL-1 values. Uncertainty factor application was the same as for the AEGL-1 derivation
 6 described above. However, no modifying factor was applied in the derivation of AEGL-2
 7 values, because the observed effects meet the definition of AEGL-2. The AEGL-2 values were
 8 held constant across time. The AEGL-3 values were based on the threshold for lethality at each
 9 AEGL-3 exposure duration calculated using the probit-analysis based dose-response program of
 10 ten Berge (2006). The assessment used rat lethality data (McNamara et al., 1969; Ballantyne and
 11 Calloway, 1972; Ballantyne and Swantson, 1978) and the LC₀₁ as the benchmark. The analysis
 12 showed a time-scaling value of 0.704 ($C^{0.704} \times t = k$). The 4-hour AEGL-3 value was adopted as
 13 the 8-hour AEGL-3 value because time scaling yielded an 8-hour value inconsistent with the
 14 AEGL-2 values that were derived from a rather robust human data set. Inter- and intraspecies
 15 uncertainty factors of 3 each were applied (total 10) and were considered sufficient because
 16 clinical signs are likely caused by a direct chemical effect on the tissues. This type of portal-of-
 17 entry effect is not likely to vary greatly between species or among individuals. The interspecies
 18 UF of 3 is supported by calculated LC_{t50} values of 88,480 mg min/m³ for rats; 67,200 mg min/m³
 19 for guinea pigs; 54,090 mg min/m³ for rabbits; and 50,010 mg min/m³ for mice (Ballantyne and
 20 Swantson, 1978), values all well within a factor of two. The intraspecies UF of 3 is supported by
 21 the fact that responses of volunteers with jaundice, hepatitis, or peptic ulcer or those that were
 22 50-60 years old were similar to those of “normal” volunteers when exposed to highly irritating
 23 concentration of CS for short durations (Punte et al., 1963; Gutentag et al., 1960).

24
 25 A motion by John Hinz (Dieter Heinz second) to accept the values as proposed including AEGL-
 26 1 values of 0.05 mg/m³ for all durations passed unanimously (Appendix E: 21 yes; 0 no; 0
 27 abstain). The AEGL-2 motion also passed (Appendix E: 21 yes; 0 no; 0 abstain), as did the
 28 AEGL-3 (Appendix E: 19 yes; 1 no; 1 abstain).

29

Summary of AEGL Values for Tear Gas						
Classification	10-min	30-min	1-h	4-h	8-h	Endpoint (Reference)
AEGL-1 (Nondisabling)	0.050 mg/m ³	Ocular/nasal irritation and headache in humans (Punte et al., 1963)				
AEGL-2 (Disabling)	0.50 mg/m ³	Ocular/nasal irritation and headache in humans (Punte et al., 1963)				
AEGL-3 (Lethal)	140 mg/m ³	29 mg/m ³	11 mg/m ³	1.5 mg/m ³	1.5 mg/m ³	Threshold for lethality (LC ₀₁) in rats [McNamara et al.(1969); Ballantyne and Calloway (1972); and Ballantyne and Swantson (1978)]

30
 31
 32

Ricin (CAS No. 9009-86-3)

Staff Scientist: Robert Young, ORNL
Chemical Manager: Jim Holler, ATSDR

Robert Young summarized the data for ricin noting that inhalation data are especially limited and that there are critical issues regarding variable potency of such a toxin (Attachment 9). Data are unavailable with which to derive AEGL-1 values and, therefore, they are not recommended (motion by John Hinz, second by Jim Holler; Appendix F: 22 yes, 0 no, 0 abstain). AEGL-2 values were initially derived based upon data in rats showing changes in pulmonary function following a single acute exposure but it was noted that this approach was tenuous. Specifically, rats exposed to a Ct of 16.7 mg•min/m³ (≈LC₂₅; considered sublethal by the investigators) showed a mild inflammatory response of insufficient severity to cause fluid accumulation in the lung or to seriously compromise the gas exchange process. The assessment was conducted at 30 hours post exposure which the investigators considered an estimated time for peak injury. Although the investigators reported no serious compromise in the gas exchange process in the lungs of the exposed rats, the arterial oxygen saturation appeared to be somewhat lower than that of unexposed controls (85% vs 90%; not statistically significant) and the exposure was noted as an LC₂₅. It was the consensus of the NAC-AEGL that this was a tenuous approach and that no AEGL-2 values be derived (motion by John Hinz, second by Jim Holler; Appendix F: 22 yes, 0 no, 0 abstain). The AEGL-3 values were based upon rat lethality data reported by Griffiths et al. (1995a). Analysis of these data using the U.S. EPA Benchmark Dose software (U.S. EPA, 2008) was limited or not possible due to varying exposure durations. Software of ten Berge (2006) was provided point estimates (LC₀₁) of 0.88, 0.28, 0.13, 0.031, and 0.0015 mg/m³, respectively, for the 10-minute, 30-minute, 1-hour, 4-hour, and 8-hour AEGL time frames based upon an exposure duration-exposure concentration relationship (ln concentration vs. ln minutes) of 0.95. These values were decreased 2.7-fold due to known variability in the potency of the ricin preparations tested. Uncertainty application used interspecies and intraspecies factors of 3 each for a total of 10. Experimental exposure durations in all of the animal studies were very short (minutes). The exposure durations used to generate the data for AEGL-3 analysis ranged from 6 to 12 minutes. Due to uncertainties in extrapolating from these very short exposure durations, 4-hour and 8-hour AEGL-3 values were not recommended. Following discussions focusing on the limited data and variable potency, the AEGL-3 values of 0.033, 0.010, and 0.0048 mg/m³ for the 10-min, 30-min. and 1-hr, respectively were adopted (Appendix F: 15 yes; 3 no; 1 abstain) following a motion by John Hinz and seconded by Jim Holler. Concern was expressed regarding the validity of 1-hour values based upon data limited to exposure duration of only several minutes.

AEGL Values for ricin (mg/m ³)						
Classification	10-min	30-min	1-h	4-h	8-h	Endpoint (Reference)
AEGL-1 (Nondisabling)	NR	NR	NR	NR	NR	Not recommended; insufficient data
AEGL-2 (Disabling)	NR	NR	NR	NR	NR	Not recommended; insufficient data
AEGL-3 (Lethality)	0.033	0.010	0.0048	NR	NR	estimated lethality threshold (LC ₀₁) in rats (Griffiths et al., 1995a); values incorporate a 2.7-fold reduction for potency variability; UF=10 (3x3); n=0.95

1
2
3
4
5
6 **Dichlorvos (CAS No. 62-73-7)**
7

8 **Staff Scientist: Jennifer Rayner, ORNL**

9 **Chemical Manager: John Hinz, AFIOH/RSRE**
10

11 Jennifer Rayner provided a review of the available data and draft AEGL values (Attachment
12 10). The draft AEGL-1 values were based on clinical exposure data showing that humans
13 exposed for 2-7 hours to ~0.11 ppm (1 mg/m³) dichlorvos experienced only inhibition of plasma
14 cholinesterase activity (Hunter 1970a). The POD was 0.11 ppm (1 mg/m³) and supported by an
15 occupational exposure data where workers exposed to an average concentration of 0.078 ppm
16 (0.7 mg/m³) dichlorvos for 8 months experienced inhibition of plasma and erythrocyte
17 cholinesterase activity but experienced no adverse health effects during or 4 months following
18 exposure (Menz et al., 1974). The interspecies uncertainty factor for AEGL-1 was 1 because
19 human data were used, and the intraspecies uncertainty factor was 1 based on oral and inhalation
20 human data showing no sex-, age-, compromised health status-related differences in response to
21 dichlorvos exposure. Following discussions, the data from Hunter (1970a) was selected as the
22 AEGL-1 values for all durations (motioned by Bob Benson; seconded by Dieter Heinz; vote 18
23 yes, 3 abstain, 0 no). The AEGL-2 values were based on a POD of 0.56 ppm (5 mg/m³) for rats
24 exposed for 45 min (Atis et al. 2002). At 1.1 and 1.7 ppm (10 and 15 mg/m³), the rats
25 experienced dyspnea, increased salivation, excessive urination and defecation, and alveolar
26 degeneration but at 0.56 ppm there were no clinical signs of toxicity. This exposure, however,
27 did cause a shortening of epithelial cells in the trachea, loss of cilia from the ciliated cells of the
28 trachea as well as alveolar interstitial thickening, capillary congestion, and extravasated
29 erythrocytes. The POD was the highest experimental value without an AEGL-2 effect. This
30 POD was also based on a 2-yr study in rats (Blair et al. 1976). The rats were exposed to
31 dichlorvos 23 hr/d and exhibited no signs of organophosphate toxicity at 0.56 ppm (5 mg
32 dichlorvos (vapor)/m³) but male rats did have decreased body weight, consistently 20% or more
33 of control male rats from the 10th week of treatment until termination. The AEGL-2 values were
34 kept constant across all time points because the 2-yr study showed that prolonged exposure
35 would not result in an enhanced effect. The interspecies uncertainty factor for AEGL-1 was 1
36 because experimental data showed that humans are no more sensitive and possibly less sensitive
37 than laboratory animals to dichlorvos, and the intraspecies uncertainty factor was 1 based on oral
38 and inhalation human data showing no sex-, age-, compromised health status-related differences
39 in response to dichlorvos exposure. Additionally, as AEGL values are set for vapor
40 concentrations, the Blair et al. (1976) vapor study shows that the POD is protective of the
41 population. The AEGL-2 values of 0.56 ppm (5 mg/m³) for all time points was unanimously
42 approved (motion by Bob Benson, second by Calvin Willhite, vote: 19 yes; 0 no; 2 abstain).
43 AEGL-3 values were not initially derived but, following committee deliberation, were based
44 upon the highest nonlethal exposure of (8 ppm [72 mg/m³] for 16 hrs) in a study by Dean and
45 Thorpe (1972a). The interspecies uncertainty factor for AEGL-1 was 1 because experimental
46 data showed that humans are no more sensitive and possibly less sensitive than laboratory
47 animals to dichlorvos, and the intraspecies uncertainty factor was 1 based on oral and inhalation
48 human data showing no sex-, age-, compromised health status-related differences in response to
49 dichlorvos exposure. The AEGL-3 values of 8.0 ppm (72 mg/m³) for all time points was
50 approved motion by Bob Benson, second by John Hinz, Appendix G: 15 yes; 0 no; 6 abstain)

1

AEGL Values for dichlorvos (ppm)						
Classification	10-min	30-min	1-h	4-h	8-h	Endpoint (Reference)
AEGL-1 (Nondisabling)	0.11	0.11	0.11	0.11	0.11	No effects in human volunteers exposed for 2-7 hours to 0.11 ppm (1 mg/m ³) (Hunter 1970a)
AEGL-2 (Disabling)	0.56	0.56	0.56	0.56	0.56	Highest experimental exposure without an AEGL-2 effect (0.56 ppm, 5 mg/m ³) (Atis et al. 2002)
AEGL-3 (Lethality)	8.0	8.0	8.0	8.0	8.0	Highest experimental exposure without a lethal effect (8.0 ppm, 72 mg/m ³) (Dean and Thorpe 1972a)

2

3

4

5

6

Dicrotophos (CAS No. 141-66-2)

7

Staff Scientist: Robert Young, ORNL

8

Chemical Manager: Bob Benson, U.S. EPA

9

10

Robert Young provided an overview of the inhalation data for this chemical (no human data and only two studies in rats) with an emphasis on the marginal nature thereof (Attachment 11). Data were not available for derivation of AEGL-1 values and AEGL-2 values. Data from one study suggested a steep exposure-response relationship which was used to justify draft AEGL-2 values as a 3-fold reduction of the AEGL-3 values. AEGL-3 values were initially based upon 1-hour and 4-hour LC₅₀ value both of which were 90 mg/m³. After a brief discussion of the data and their limitations, it was moved by Bob Benson to defer further discussion of this chemical to the next meeting and reconsider dicrotophos in conjunction with monocrotophos. A motion to this effect was made by Bob Benson, second by Calvin Willhite, and passed unanimously by a show of hands.

21

22

23

24

Fenamiphos (CAS No. 22224-92-6)

25

Staff Scientist: Jennifer Rayner, ORNL

26

Chemical Manager: George Woodall, U.S. EPA

27

28

Jennifer Rayner provided a brief overview the limited data for this chemical (Attachment 12). An attempt will be made to obtain a non-sanitized copy of a Bayer Corp. study (Thyssen, 1979) on the 4-hr exposure of rats which may of use in developing AEGL values. If obtained, these data may be used for 4-hr BMC analysis and ten Berge calculations. Further deliberations on this chemical were tabled (unanimous vote by show of hands).

34

35

36

Malathion (CAS No. 121-75-5)

37

Staff Scientist: Carol Wood, ORNL

38

Chemical Manager: John Hinz, AFIOH/RSRE

39

40

1 Carol Wood presented an overview of the draft TSD for malathion (Attachment 13). AEGL-1
 2 and AEGL-2 were based upon data from a subchronic inhalation study in Sprague-Dawley rats
 3 (US EPA 2000) exposed to malathion (96.4% a.i.) aerosols (in air) at concentrations of 0, 100,
 4 450 or 2010 mg/m³, 6 hours/day, 5 days/week for 13 weeks. The 6-hour exposure to 450 mg/m³
 5 was chosen as the POD for derivation of AEGL-1 values. Because clinical signs at the point of
 6 departure were sporadic and cholinesterase activity inhibition was not biologically significant
 7 after the 13-week exposure, time scaling was not performed. The total uncertainty factor of 30
 8 includes 10 for intraspecies extrapolation to account for the documented variability in sensitivity
 9 among different age groups and genders, and the known genetic polymorphisms in A-esterases
 10 and 3 for interspecies extrapolation to account for the differences in serum carboxylesterase
 11 levels between humans and rats. The 2010 mg/m³ exposure for 6 hours was the POD for AEGL-
 12 2 values. Critical effects after 13-week exposure included microscopic lesions and significant
 13 inhibition of brain cholinesterase activity. A total uncertainty factor of 30 was applied as for
 14 AEGL-2 with time scaling using default values of n = 3 for extrapolating to the 30-minute, 1-
 15 hour, and 4-hour time points and n = 1 for the 8-hour time point (30-minute value was adopted as
 16 the 10-minute AEGL-2 value as per AEGL SOP). A motion to accept the AEGL-1 and AEGL-2
 17 values as presented was made by Bob Benson and second by Jim Holler. The motion passed
 18 (Appendix H: 21 yes, 0 no, 0 abstain). AEGL-3 values for malathion were not recommended in
 19 the draft TSD. Following discussion, the NAC/AEGL decided to base AEGL-3 values on a POD
 20 of 6900 mg/m³ (5-hr exposure) which represented the highest exposure for any species. The
 21 uncertainty factor application (total of 30) and time scaling (default) were as for AEGL-1 and
 22 AEGL-2. AEGL-3 values (expressed as mg/m³) of 500, 500, 390, 250, and 140 for 10-min, 30-
 23 min, 1-hr- 4-hrs, and 8-hrs, respectively were adopted (motion by Bob Benson, second by Jim
 24 Holler; Appendix H: 16 yes; 2 no; 3 abstain). It was decided to include a footnote for the AEGL-
 25 3 values noting that lethal air concentrations are unavailable for humans and animals and that
 26 lethal air concentrations may not be attainable.
 27

AEGL Values for Malathion						
Classification	10-minute	30-minute	1-hour	4-hour	8-hour	Endpoint (Reference)
AEGL-1 (Nondisabling)	15 mg/m ³	Sporadic clinical signs in rats (US EPA 2000)				
AEGL-2 (Disabling)	150 mg/m ³	150 mg/m ³	120 mg/m ³	77 mg/m ³	50 mg/m ³	Clinical signs in rats (US EPA 2000)
AEGL-3* (Lethal)	500 mg/m ³	500 mg/m ³	390 mg/m ³	250 mg/m ³	140 mg/m ³	6900 mg/m ³ (5-hr exposure); highest available exposure for any species

28 * Although no lethality has been reported in humans or animals from inhalation exposure to malathion, AEGL-3
 29 values are derived to serve as guidance in an emergency situation. It is acknowledged that attaining lethal airborne
 30 concentrations of malathion may not be possible.
 31
 32

33 Mevinphos (CAS No. 7786-34-7)

34
 35 **Staff Scientist: Jennifer Rayner, ORNL**

36 **Chemical Manager: Daniel Sudakin, Oregon St. Univ.**
 37

38 Jennifer Rayner reviewed the extremely limited information on this chemical (Attachment 14).
 39 The low vapor pressure of mevinphos likely precludes significant inhalation exposure and route-

1 to-route extrapolation may be considered. The possibility of a position paper on route-to-route
2 extrapolation was discussed. The SOP addressed this issue but does not provide specific
3 guidance on procedures/methods. Paul Tobin will work with OPP to come up with a scientific
4 approach for the pesticides of AEGL concern. Gail Chapman also mentioned the availability of
5 cholinesterase inhibition data in one of the mevinphos papers and queried how these data might
6 be used in the mevinphos assessment. Deliberation on mevinphos was deferred until “credible”
7 route-to-route extrapolation procedures are investigated.

8
9
10 **Bromoacetone (CAS No. 598-31-2)**

11
12 **Staff Scientist: Cheryl Bast, ORNL**

13 **Chemical Manager: Roberta Grant, TX Commission Environ. Quality**

14
15 Cheryl Bast presented an overview of the data and draft AEGL values (Attachment 15).
16 Proposed AEGL-1 values were based on a concentration causing ocular irritation in 2/6 humans
17 (0.1 ppm) (Dow Chemical, 1968). An intraspecies uncertainty factor of 3 was applied because
18 contact irritation is a portal of entry effect and is not expected to vary widely between
19 individuals. An interspecies uncertainty factor of 1 was applied because the study was
20 conducted in humans. Time scaling was not applied in the development of the AEGL-1 values.
21 The critical effect (ocular irritation) is a function of direct contact with the bromoacetone vapor
22 and not likely to increase with duration of exposure (NRC, 2001). However, because of the lack
23 of human data beyond a few seconds, a modifying factor of 3 was applied. Although the
24 concentration-response relationship for bromoacetone is not particularly steep, the AEGL-3
25 values were divided by 3 to derive proposed AEGL-2 values for bromoacetone. This approach
26 was utilized because use of the rat irritation data as a point-of-departure yields AEGL-2 values
27 essentially identical to AEGL-3 values calculated from lethality data.

28
29 Proposed AEGL-3 values were based on rat lethality data of varying exposure
30 concentrations and durations (Dow Chemical, 1968). Experimental concentrations ranged from
31 1 to 131 ppm and durations ranged from 6 to 120 minutes. The threshold for lethality at each
32 AEGL-3 exposure duration was calculated using the probit-analysis based dose-response
33 program of ten Berge (2006). The threshold for lethality was set at the LC_{01} . The data indicated
34 a time-scaling value of 1.256 ($C^{1.256} \times t = k$). These calculated values were used as the basis for
35 the AEGL-3 values. Inter- and intraspecies uncertainty factors of 3 each were applied (total 10)
36 and are considered sufficient because bromoacetone is an irritant (lacrimation, nasal discharge,
37 gasping, wheezing, and labored breathing in rats and ocular irritation in humans; Dow Chemical,
38 1968) and clinical signs are likely caused by a direct chemical effect on the tissues. This type of
39 portal-of-entry effect is not likely to vary greatly between species or among individuals.

40
41 Calvin Willhite suggested mentioning chloroacetone in the structure-activity section of the TSD.
42 A motion was made by Calvin Willhite (second by Gail Chapman) to adopt the AEGL values as
43 presented. The motion passed (Appendix I: 19 yes; 0 no; 0 abstain).

A EGL Values for Bromoacetone (ppm)						
Classification	10-minute	30-minute	1-hour	4-hour	8-hour	Endpoint (Reference)
A EGL-1 (Nondisabling)	0.011 ppm	Ocular irritation in humans (Dow Chemical, 1968)				
A EGL-2 (Disabling)	1.4 ppm	0.57 ppm	0.33 ppm	0.11 ppm	0.063 ppm	One-third the A EGL-3 Values
A EGL-3 (Lethal)	4.1 ppm	1.7 ppm	0.98 ppm	0.32 ppm	0.19 ppm	Threshold for lethality (LC ₀₁) in rats (Dow Chemical, 1968)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

Phosphorus Pentachloride (CAS No. 10026-13-8)

Staff Scientist: Carol Wood, ORNL
Chemical Manager: Bob Benson, U.S. EPA

Bob Benson, chemical manager, made brief introductory remarks. Carol Wood, author of the TSD, then presented a discussion of the inhalation data available for the chemical (Attachment 16). The human data consisted of a case report of an industrial accident, a laboratory animal study available only in a secondary report, and another laboratory animal study with only limited experimental details presented (Molodkina, 1973). After a brief discussion of the feasibility of using data on PCl_3 or $POCl_3$ to derive values for PCl_5 , Bob Benson moved that the chemical be placed in holding status and request that ORNL try to obtain additional information from the producer of the chemical. Dieter Heinz seconded the motion. The motion was approved unanimously by non-ballot vote (Appendix J).

Nitrogen Trifluoride (CAS No. 7783-54-2)

Staff Scientist: Sylvia Talmage, ORNL
Chemical Manager: Bob Benson, U.S. EPA

Bob Benson, chemical manager, made brief introductory remarks. Sylvia Talmage, author of the TSD, then presented a discussion of the inhalation data available for the chemical (Attachment 17). There are no human data available. However, there is a fairly robust data set in laboratory animals with lethality studies in four species with less than a two-fold difference in response. There are also repeat-exposure and subchronic studies in rats, developmental/reproductive studies in rats, and genotoxicity studies. For A EGL derivation the primary effect is the formation of methemoglobin. Data from the dog, the most appropriate species, was used to derive all A EGL values. For all values an interspecies UF of 1 and an intraspecies UF of 10 were used. Time scaling was done with the experimentally derived $n = 1$ from the lethality studies using the ten Berge (2006) regression analysis program. Draft A EGL-1 values for the formation of 15% methemoglobin were 1200 ppm, 400 ppm, 200 ppm, 50 ppm, and 25 ppm for 10 minutes to 8 hours, respectively. Draft A EGL-3 values for the formation of 70% methemoglobin were 5000 ppm, 1700 ppm, 860 ppm, 220 ppm, and 110 ppm for 10 minutes to 8 hours, respectively. Draft A EGL-2 values were derived by averaging A EGL-1 and A EGL-3

1 values and correspond to the formation of 42% methemoglobin with values of 3100 ppm, 1100
 2 ppm, 530 ppm, 140 ppm, and 68 ppm for 10 minutes to 8 hours, respectively. Aniline
 3 methemoglobin information was used as a reference for nitrogen trifluoride. Bob Benson moved
 4 that these values be accepted. Mark Baril seconded the motion. The motion passed (Appendix
 5 K: 19 yes; 0 no; 1 abstain).

AEGL Values for Nitrogen Trifluoride (ppm)						
Classification	10-minute	30-minute	1-hour	4-hour	8-hour	Endpoint (Reference)
AEGL-1 (Nondisabling)	1200 ppm	400 ppm	200 ppm	50 ppm	25 ppm	≤15% methemoglobin formation in monkeys and dogs following 60-minute exposure to 2000 ppm (Vernot et al. 1973)
AEGL-2 (Disabling)	3100 ppm	1100 ppm	530 ppm	140 ppm	68* ppm	Estimated 43% methemoglobin in dogs: midpoint of AEGL-1 and AEGL-3 (Vernot et al. 1973)
AEGL-3 (Lethal)	5000 ppm	1700 ppm	860 ppm	220 ppm	110 ppm	Regression analysis of dog lethality data of Vernot et al. (1973) calculated with the ten Berge (2006) program

*Due to a typographical error in presentation material, the balloted value was 55 ppm.

ADMINISTRATIVE MATTERS

Future Meetings:

April 14-16, 2009 in Alexandria, VA.

September 9-11, 2009 (Paris, Montreal or Denver)

December 2-4, 2009 (perhaps Orlando, Florida)

All items in the agenda were discussed as thoroughly as the time permitted. The meeting highlights were prepared by Cheryl Bast, Sylvia Talmage, and Robert Young, Oak Ridge National Laboratory, and Bob Benson and Iris Camacho, U.S. EPA.

LIST OF ATTACHMENTS

The attachments were distributed during the meeting and will be filed in the EPA Docket Office.

- Attachment 1. Meeting 47 agenda
- Attachment 2. Meeting 47 attendee list
- Attachment 3. Chlorosilanes presentation
- Attachment 4. Acrylonitrile response to FR comments presentation
- Attachment 5. OP issues-Virginia Moser presentation
- Attachment 6. Allyl alcohol- LyondelleBasell/Fowles
- Attachment 7. Allyl alcohol presentation- Troxel/Benson
- Attachment 8. Tear gas presentation
- Attachment 9. Ricin presentation
- Attachment 10. Dichlorvos presentation
- Attachment 11. Dicrotophos presentation
- Attachment 12. Fenamiphos presentation
- Attachment 13. Malathion presentation
- Attachment 14. Mevinphos presentation
- Attachment 15. Bromoacetone presentation
- Attachment 16. Phosphorus pentachloride presentation
- Attachment 17. Nitrogen trifluoride presentation
- Attachment 18. NAC- 47 meeting certification

LIST OF APPENDICES

- Appendix A. Ballot for approval of NAC-46 meeting highlights
- Appendix B. Final NAC-46 Meeting Highlights
- Appendix C. Ballot for chlorosilanes
- Appendix D. Ballot for allyl alcohol
- Appendix E. Ballot for tear gas
- Appendix F. Ballot for ricin
- Appendix G. Ballot for dichlorvos
- Appendix H. Ballot for malathion
- Appendix I. Ballot for bromoacetone
- Appendix J. Ballot for phosphorus pentachloride
- Appendix K. Ballot for nitrogen trifluoride